Sylvan Learning Launches $29 Assessments to Combat Pandemic and Summer Learning Loss
Limited-time discounted assessments are available April 14 - May 25 to help families identify learning gaps before summer break widens them further.
DALLAS, April 16, 2025 /PRNewswire-PRWeb/ -- As the school year winds down and families gear up for summer, Sylvan Learning is offering a timely solution to one of education's biggest challenges: identifying and addressing learning gaps before they grow even wider during the summer break. From April 14 through May 25, Sylvan is offering its proprietary Insight™ Assessment for just $29, helping families pinpoint where their children stand academically as they navigate the dual impact of post-pandemic learning disruptions and summer learning loss. The move comes in response to recent findings from the National Assessment of Educational Progress (NAEP), which show that U.S. students are still grappling with academic setbacks caused by the COVID-19 pandemic. Reading scores for 13-year-olds have plummeted to the lowest levels since 1975, and nearly one in three students is performing below basic proficiency in both math and reading.
But COVID isn't the only culprit. According to a report from Northwest Evaluation Association (NWEA), students can lose up to two to three months of academic progress over the summer if they're not engaged in learning activities — and the effect is even more pronounced for students who are already behind. "The national data confirms what we've been seeing in our centers for the past few years — students are still catching up," said Susan Valverde, brand president of Sylvan Learning. "Unfortunately, many families don't know their children are behind because report cards don't always tell the full story. Our $29 assessment gives parents a clear, accurate view of where their child stands, so they can take action before it's too late."
Sylvan's Insight™ Assessment is an adaptive, in-person evaluation administered by education professionals at local centers. It covers key skill areas in reading, writing, and math, and includes a one-on-one consultation with parents to go over the results and create a personalized learning plan tailored to the student's needs. "With so much variation in how schools are grading and measuring progress, families need an independent, reliable way to understand what their children actually know," Valverde said. "Whether your child is struggling or just not being challenged enough, this assessment is a powerful first step."
Experts say summer is a critical time for intervention, especially for students who were already facing academic challenges before the pandemic. "It's not just that achievement is lower on average, but we're also seeing a widening gap between high and low achievers," said Karyn Lewis, director of the Center for School and Student Progress at NWEA. "This suggests the pandemic had a more profound effect on students who were already struggling." That's why Sylvan is making it easier for parents to take action before the summer break begins. With more than 45 years of experience in supplemental education, Sylvan has expanded its reach through school partnerships, government-funded programs, and targeted tutoring efforts across the country. From Louisiana's literacy voucher initiative to district-level support in California, Sylvan centers are helping thousands of students rebuild confidence and close critical academic gaps. "Our mission is to make high-quality education accessible to every student," Valverde said. "And that begins with knowledge. When parents know where their child stands, they can make the best decisions to support their academic journey — and we're here to help every step of the way."
To learn more about your closest Sylvan Learning location offering a discounted assessment, visit http://www.SylvanLearning.com.
ABOUT SYLVAN LEARNING With more than 45 years of experience and more than 710 points of presence, Sylvan Learning is the leading provider of personal learning for students in grades K-12. Sylvan is transforming how students learn, inspiring them to succeed in school and in life. Sylvan's proven tutoring approach blends amazing teachers with SylvanSync™ technology on the iPad® for an engaging learning experience. Sylvan also leads the way with Sylvan EDGE — STEM and accelerated courses and Sylvan Prep — college and test prep courses. Sylvan supports families through every stage of the academic journey. For more information, visit http://www.SylvanLearning.com.
ABOUT UNLEASHED BRANDS Unleashed Brands currently includes portfolio brands Urban Air, The Little Gym, Sylvan Learning, Snapology, XP League, Class 101, Premier Martial Arts and Water Wings Swim School. The platform was founded to curate and grow a portfolio of the most innovative and profitable franchise brands that help kids learn, play, and grow. Over the last 10 years, the team at Unleashed Brands has built a proven platform for scaling businesses focused on serving families. Its mission is to impact the lives of every child by providing fun, engaging, and inspiring experiences that help them reach their full potential. For more information, visit UnleashedBrands.com.
Media Contact
Lauren Turner, Mainland, 3125263996, lturner@hellomainland.com, www.hellomainland.com
View original content:https://www.prweb.com/releases/sylvan-learning-launches-29-assessments-to-combat-pandemic-and-summer-learning-loss-302430257.html
SOURCE Sylvan Learning
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Ramey v. Penn State University: Class action lawsuit payments distributed to students
(WHTM) – Penn State University students who were enrolled in classes at the start of the COVID-19 pandemic are now receiving part of a $17 million class action settlement. On March 16, 2020, the university moved to 'remote instruction' due to the outbreak of COVID-19. Years later, a class action lawsuit was brought on behalf of those who paid tuition and/or fees for the Spring 2020 semester and registered for a class. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now The lawsuit was brought forward with allegations of a breach of contract by the university for not providing the services promised with tuition and fees. The university denied the claims asserted against it and agreed to the $17 million settlement for students who opted in to the lawsuit, known as 'Ramey et al. v. The Pennsylvania State University.' A court granted final approval of the settlement on February 18, 2025, and the deadline to file a claim has since passed. According to the Penn State Tuition Refund Settlement website, payments to eligible class members were sent on June 5, 2025. The website says those who opted to receive payments should have received notification of their award via email and should expect a check in the mail. Payments were automatically sent to the recipients' 'last known permanent postal address on file with Penn State,' according to the settlement website. The deadline to change that address or type of payment has also passed. Of the $17 million in settlement funds, the final judgment awarded attorneys' fees of $5,666,100, deducted litigation expenses worth $17,990.94, and made a $15,000 award for the individuals who initiated the lawsuit. The remaining portion of the money (approximately $11,300,909) was designated as the 'Net Settlement Fund.' Students eligible for payments 'who withdrew for medical reasons from Penn State after March 16, 2020, but before the conclusion of the Spring 2020 semester, and received a refund of tuition,' will receive $50 from the Net Settlement Fund. The remaining funds were then 'distributed equally to all other Settlement Class Members.' Eligible students included those attending branch campuses at the time of the shutdown, according to the settlement. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. COVID vaccine maker BioNTech is buying rival CureVac, announcing Thursday an all-stock deal weeks before the two companies were due to face off in a German court over potentially billions of dollars worth of royalties related to intellectual property on messenger RNA drugs. Per deal terms, each CureVac share will be exchanged for about $5.46 worth of BioNTech's U.S.-listed shares, valuing the company at $1.25 billion. Upon the deal's close, CureVac shareholders will own between 4% and 6% of BioNTech. In the early days of the COVID-19 pandemic, BioNTech and CureVac were among the companies racing to develop the first coronavirus vaccines. BioNTech, however, partnered with Pfizer and won approval of the first COVID-19 shot, while CureVac's program never made it to market. The two companies have since been embroiled in patent litigation. CureVac was a leading candidate to develop the first COVID-19 vaccine, launching rumors, later denied, that the U.S. government might even buy the company or its research. But while BioNTech and fellow mRNA drugmaker Moderna succeeded in making vaccines that saved millions of lives and earned billions of dollars in revenue, CureVac fell short. Its initial project wasn't effective enough at preventing sickness, prompting it to scrap development. A year later, CureVac sued BioNTech, claiming it infringed four patents. CureVac has since changed course, selling off most rights to influenza and COVID-19 vaccines to partner GSK and focusing on cancer instead. But its legal spat with BioNTech has lingered. The European Patent Office had upheld two CureVac patents, and a trial in a Dusseldorf regional court was set on July 1 to determine if BioNTech had infringed on them. A separate trial in the U.S. was scheduled to begin Sept. 8 in Virginia. Some Wall Street analysts, as a result, speculated that BioNTech's primary purpose is buying CureVac is to sidestep the risk of a loss in court. A single-digit percentage royalty awarded to CureVac could've cost BioNTech as much as $3 billion, Evercore ISI analyst Umer Raffat wrote in a note to clients. 'It seems to us that [BioNTech] assessed the cost of a cash settlement as substantially greater than the cost of buying [CureVac] outright,' Raffat wrote. The deal could also help BioNTech further its oncology ambitions. Like CureVac, BioNTech has made cancer research a top priority. It's invested in a variety of programs, from cell therapies to mRNA vaccines and a coveted type of bispecific antibody. Some are in advanced testing. CureVac's cancer vaccines are in earlier phases of development. A brain cancer shot has delivered early clinical data, while a lung cancer immunotherapy was cleared in April for human testing. The deal should help CureVac because of 'the early stage of the oncology pipeline and the need for a development partner to effectively compete in personalized cancer vaccines – which [BioNTech] is well positioned to execute,' wrote Leerink Partners analyst Mani Foroohar. Raffat, of Evercore ISI, however, wrote that the deal ascribes 'very little value' to CureVac's pipeline. Recommended Reading Recursion to acquire two Canadian drug discovery startups Sign in to access your portfolio